Francisco Salva
Algemeen Directeur bij AZITRA, INC.
Vermogen: 74 426 $ op 30-04-2024
Oorsprong van het eerstegraads netwerk van Francisco Salva
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 21 | |
Acerta Pharma BV
 Acerta Pharma BV Pharmaceuticals: GenericHealth Technology Acerta Pharma BV develops drugs for oncology and autoimmune diseases. It operates as a biotech company that combines technology platforms in drug discovery and development such as the covalent technology platform and the multiparametric phosphoflow cytometry platform. The company was founded by Allard Kaptein in 2012 and is headquartered in Oss, Netherlands.
9
| Subsidiary | Pharmaceuticals: Generic | 9 |
| Public Company | Pharmaceuticals: Major | 7 | |
Complexa, Inc.
 Complexa, Inc. Pharmaceuticals: MajorHealth Technology Complexa, Inc. operates as a biopharmaceutical company which engages on discovering and developing therapies for the treatment of severe and life-threatening fibrosis and inflammatory diseases. The firm focuses on two therapeutic areas: focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH), two rare diseases that can compromise the normal function of the kidney and the heart. The company was founded by Bruce A. Freeman, Raymond A. Miller, and Margaret M. Tarpey in 2008 and is headquartered in Berwyn, PA.
4
| Extinct | Pharmaceuticals: Major | 4 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Francisco Salva via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| ABBOTT LABORATORIES | Medical Specialties | Director/Board Member Corporate Officer/Principal | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal | |
| GILEAD SCIENCES, INC. | Biotechnology | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal | |
| PHARMACYCLICS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Frazier Management LLC
 Frazier Management LLC Investment ManagersFinance Frazier Management LLC (Frazier Healthcare Partners) is a venture capital subsidiary of Frazier & Co Inc. founded in 1991. The firm is headquartered in Seattle, Washington. | Investment Managers | Consultant / Advisor Private Equity Investor | |
Presage Biosciences, Inc.
 Presage Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Presage Biosciences, Inc. engages in development of novel drugs for treatment of cancers. It offers CIVO arrayed microinjection platform that allows for simultaneous assessment of multiple drugs or drug combinations directly in a single solid tumor while still in a patient’s body to assess efficacy, resistance, and drug synergies in the tumor’s native microenvironment. The company was founded by James M. Olson and Thane Kreiner in 2008 and is headquartered in Seattle, WA. | Pharmaceuticals: Major | Chairman | |
| AURA BIOSCIENCES, INC. | Biotechnology | Chairman | |
Johnson & Johnson Innovation - JJDC, Inc.
 Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC Inc (Johnson & Johnson Innovation JJDC) is a venture capital subsidiary of Johnson & Johnson founded in 1973. The firm is headquartered in New Brunswick, New Jersey. | Investment Managers | Corporate Officer/Principal | |
| Stanford University | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | College/University | Undergraduate Degree Undergraduate Degree | |
| University of Pennsylvania | College/University | Undergraduate Degree Graduate Degree | |
Roche Group
 Roche Group Real Estate DevelopmentFinance Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland. | Real Estate Development | Corporate Officer/Principal | |
Quogue Capital LLC
 Quogue Capital LLC Investment ManagersFinance Quogue Capital LLC (Quogue Capital) is a private equity firm founded in 2002 by Wayne P. Rothbaum. The firm is headquartered in New York. | Investment Managers | Founder Director of Finance/CFO | |
| Xavier University | College/University | Masters Business Admin | |
| University of California, Los Angeles | College/University | Doctorate Degree Corporate Officer/Principal | |
| Indiana University | College/University | Undergraduate Degree | |
The Ohio State University
 The Ohio State University Other Consumer ServicesConsumer Services Global Factory, Inc. provides collaborative manufacturing execution systems. The firm's software gather, organize & analyze demand, production & quality data from various sources and monitor key indicators & execute business processes to control, manage & optimize distributed manufacturing operations. The company was founded in 1999 and is headquartered in Santa Clara, CA. | College/University | Corporate Officer/Principal Corporate Officer/Principal | |
| University of California, Berkeley | College/University | Undergraduate Degree Doctorate Degree Doctorate Degree | |
| University of California San Diego | College/University | Doctorate Degree Undergraduate Degree | |
| University of California, Santa Barbara | College/University | Graduate Degree Undergraduate Degree | |
| University of Massachusetts | College/University | Undergraduate Degree Graduate Degree | |
| Università degli Studi di Modena e Reggio Emilia | College/University | Doctorate Degree | |
| CANTARGIA AB | Pharmaceuticals: Major | Director/Board Member | |
| IOVANCE BIOTHERAPEUTICS, INC. | Biotechnology | Director/Board Member Chief Executive Officer | |
| University of California | College/University | Director/Board Member Doctorate Degree | |
Andes Biotechnologies SA
 Andes Biotechnologies SA BiotechnologyHealth Technology Andes Biotechnologies SA researches and develops effective treatments against cancer. It has developed a new proprietary technology based on the discovery of a novel family of RNA targets of mitochondrial origin that when disrupted by anti-sense technology they selectively destroy cancer cells. The company was founded by Luis O. Burzio, Arturo Yudelevich and Pablo D.T. Valenzuela in 2008 and is headquartered in Santiago, Chile. | Biotechnology | Director/Board Member Director/Board Member | |
| REVOLUTION MEDICINES, INC. | Pharmaceuticals: Other | Director/Board Member | |
NantCell, Inc.
 NantCell, Inc. Pharmaceuticals: MajorHealth Technology NantCell, Inc. focuses on treating immunology diseases. It offers cell-based treatments at the molecular level. The firm develops molecularly designed drugs for genomics and proteomics and identify patients and their tumor signature at the granular cellular, DNA and protein levels. The company was founded by Patrick Soon-Shiong in 2014 and is headquartered in Culver City, CA. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Oncternal Oncology, Inc.
 Oncternal Oncology, Inc. Pharmaceuticals: MajorHealth Technology Oncternal Oncology, Inc. is a clinical-stage oncology company, which engages in the development of novel therapies for both rare and common cancers. The company was founded by Lauren Otsuki and Cam L. Garner and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Chairman | |
| PRELUDE THERAPEUTICS INCORPORATED | Biotechnology | President | |
Palleon Pharmaceuticals, Inc.
 Palleon Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA. | Miscellaneous Commercial Services | Director/Board Member | |
| RAFAEL HOLDINGS, INC. | Real Estate Development | Investor Relations Contact Director/Board Member | |
Kartos Therapeutics, Inc.
 Kartos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kartos Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Redwood City, CA. Kartos Therapeutics, Inc. is focused on developing a potential MDM2 inhibitor for the treatment of various TP53 wild-type hematological malignancies and solid tumors. The company was founded by Wayne P. Rothbaum and Iain David Dukes, and the CEO is Jesse Seton McGreivy. | Pharmaceuticals: Major | Founder Director/Board Member Director/Board Member Director/Board Member | |
| ZENTALIS PHARMACEUTICALS, INC. | Biotechnology | Chairman | |
| Acerta Pharma LLC | Founder Corporate Officer/Principal Chief Operating Officer Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | ||
| Baskin School of Engineering | College/University | Corporate Officer/Principal Corporate Officer/Principal | |
Lengo Therapeutics, Inc.
 Lengo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lengo Therapeutics, Inc. operates as a pharmaceutical company. The company is headquartered in Menlo Park, CA. | Pharmaceuticals: Major | Director/Board Member Chairman | |
| IMMUNITYBIO, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
LifeSci Acquisition III Corp.
 LifeSci Acquisition III Corp. Financial ConglomeratesFinance LifeSci Acquisition III Corp. operates as a blank check company with the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination. The company was founded on December 18, 2019 and is headquartered in new York, NY. | Financial Conglomerates | Chief Executive Officer Director/Board Member | |
| VIRACTA THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
858 Therapeutics, Inc.
 858 Therapeutics, Inc. BiotechnologyHealth Technology 858 Therapeutics, Inc. operates as a pharmaceutical company. The company was founded in 2019 and is headquartered in San Diego, CA. | Biotechnology | Director/Board Member | |
| PROTARA THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member |
Statistieken
Internationaal
| Verenigde Staten | 43 |
| Verenigd Koninkrijk | 2 |
| Zwitserland | 2 |
| China | 2 |
| Italië | 2 |
Sectoraal
| Health Technology | 25 |
| Consumer Services | 15 |
| Finance | 7 |
| Commercial Services | 3 |
| Process Industries | 2 |
Operationeel
| Director/Board Member | 112 |
| Corporate Officer/Principal | 100 |
| Chief Tech/Sci/R&D Officer | 41 |
| Founder | 35 |
| Independent Dir/Board Member | 34 |
Sterkste connecties
| Insiders | |
|---|---|
| Christopher Lowe | 25 |
| Andrew McDonald | 19 |
| Barbara Ryan | 18 |
| Roger Ulrich | 17 |
| Diane Jorkasky | 15 |
| Maria Fardis | 15 |
| Mark McCamish | 15 |
| Ahmed Hamdy | 14 |
| John Lee | 14 |
| Alexander Seelenberger Farba | 13 |
| John R. Schroer | 12 |
| Xiaoming Zhang | 11 |
| David Johnson | 11 |
| Jeanne M. Bertonis | 11 |
| Elsa Johnson | 10 |
- Beurs
- Insiders
- Francisco Salva
- Bedrijfsconnecties
